| CPC C12N 9/22 (2013.01) [C12N 15/102 (2013.01); C12N 15/1089 (2013.01); C12N 15/86 (2013.01); G16B 20/00 (2019.02); G16B 30/10 (2019.02); G16B 30/20 (2019.02); C12N 2310/20 (2017.05); C12N 2710/10343 (2013.01); C12N 2740/16043 (2013.01); C12N 2750/14143 (2013.01); C12N 2800/80 (2013.01)] | 14 Claims |
|
1. A method for preparing a Type II or a Type V CRISPR-Cas guide molecule comprising:
selecting a set of candidate therapeutic target sequences for one or more loci in a target population, wherein the candidate therapeutic target sequences do not contain variants occurring above a threshold allele frequency in the target population;
removing any candidate therapeutic target sequences having off-target candidates in haplotypes that occur in at least 0.1% of the target population from the set of candidate therapeutic target sequences to thereby define a final target sequence set; and
preparing one or more guide molecules based on the final therapeutic target sequence set targeting one or more loci associated with a disease or disorder.
|